Provided by Tiger Fintech (Singapore) Pte. Ltd.

HENLIUS

40.350
+1.4003.59%
Volume:926.69K
Turnover:36.34M
Market Cap:21.93B
PE:24.94
High:40.400
Open:38.950
Low:37.800
Close:38.950
Loading ...

Shanghai Henlius Biotech Inc - DR. Reddy's Shall Pay Company US$33 Mln

THOMSON REUTERS
·
06 Feb

Shanghai Henlius Biotech's Anti-Lung Cancer Injection Gets European Commission's Approval

MT Newswires Live
·
06 Feb

BRIEF-Shanghai Henlius Biotech Says European Commission Approved Serplulimab Injection

Reuters
·
06 Feb

BRIEF-Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Reuters
·
05 Feb

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (Es-Sclc)

THOMSON REUTERS
·
05 Feb

Shanghai Henlius Biotech Inc - European Commission Approved Serplulimab Injection in Combination With Chemotherapy

THOMSON REUTERS
·
05 Feb

Shanghai Henlius Biotech's License Application for Breast Cancer Drug Gets FDA Nod

MT Newswires Live
·
03 Feb

Henlius Biotech's Merger Contract with Fosun Pharma Falls Through; Shares Fall 4%

MT Newswires Live
·
23 Jan

Stock Track | HENLIUS Plummets 10.53% as Shareholders Reject Fosun's Buyout Offer

Stock Track
·
23 Jan

BUZZ-Shanghai Henlius Biotech at 9-month low as shareholders reject buyout offer

Reuters
·
23 Jan

Henlius Biotech shareholders reject take-private offer from China's Fosun

Reuters
·
22 Jan

BRIEF-Fosun Pharmaceutical To Buy Back Shares

Reuters
·
22 Jan

Shanghai Fosun Pharmaceutical Says Unit's Plan to Merge With Henlius Biotech Failed to Pass Henlius's Shareholder Meeting

THOMSON REUTERS
·
22 Jan

Rpt-Shanghai Fosun Pharma - Merger Was Not Approved at H Shareholders' Class Meeting.

THOMSON REUTERS
·
22 Jan

BRIEF-Shanghai Fosun Pharma Says Privatisation Of Shanghai Henlius Biotech Will Not Proceed

Reuters
·
22 Jan

Corrected-Shanghai Fosun Pharma - Proposed Privatisation of Shanghai Henlius Biotech (Not Co) Will Not Proceed and Listing of H Shares on Main Board of Stock Exchange Will Be Maintained

THOMSON REUTERS
·
22 Jan

Henlius Get China Nod for Tumor Drug Clinical Trial

MT Newswires Live
·
13 Jan

BRIEF-Shanghai Henlius Biotech Says Application For Phase 1B/2 Clinical Trial Of Hlx43- For Injection In- Combination With Hansizhuang Approved By NMPA

Reuters
·
10 Jan

Shanghai Henlius Biotech Inc - Application for Phase 1B/2 Clinical Trial of Hlx43- for Injection in- Combination With Hansizhuang Approved by Nmpa

THOMSON REUTERS
·
10 Jan

Essex Bio-Technology Unit's Co-Developed Drug Completes LPLV for Phase 3 Clinical Study

MT Newswires Live
·
06 Jan